Quarterly Financial Results for Q2 2026 - Contains consolidated financial statements for the six-month period ended June 30, 2026 and the three-month period ended June 30, 2026, compared to the same periods in 2025 Balance Sheet and Equity Information - Presents detailed stockholders' equity components including common stock, additional paid-in capital, retained earnings, accumulated other…

Our analysis rates this filing CAUTIOUS. Quest Diagnostics faces an ELEVATED concern profile driven by multiple material risks in a INCREASING trend. The two severity-7 risks—contingent consideration valuation volatility and industry-wide reimbursement/competitive pressures—represent meaningful…

Concern level: HIGH (6.8/10). Key factors: Two high-severity risks identified (severity 7/10): Haystack Oncology contingent consideration valuation volatility and medical laboratory industry reimbursement/competitive pressures; Risk trend is INCREASING with overall risk score of 6.8, indicating deteriorating risk profile; Haystack Oncology contingent consideration shows active fair value…

Notable risk changes: Corewell Health acquisition closed January 31, 2026 - new integration risk and potential earnout liabilities not fully disclosed; customer relationship intangibles subject to impairment risk if synergies fail to materialize; Haystack Oncology contingent consideration remains material liability with high fair value volatility - Q2 2026 shows active remeasurement driven by changes in discount…

The model predicts DGX will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.